Atomoxetine - Revision history

MDElliottMD: parser-claude: Atomoxetine MedTemplate refill, Top 300 stub upgrade

2026-05-23T07:08:14Z

parser-claude: Atomoxetine MedTemplate refill, Top 300 stub upgrade

← Older revision		Revision as of 07:08, 23 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	\| generic = Atomoxetine		\| generic = Atomoxetine
	\| brand = Strattera		\| brand = Strattera
	\| structure =		\| structure =
	\| classes = ~~NRI, ADHD medicine~~		\| classes = [[:Category:NRIs\|Selective norepinephrine reuptake inhibitor (NRI)]], [[:Category:ADHD medicines\|ADHD medicine]]
	\| ~~mechanism =~~ Selective norepinephrine reuptake inhibitor		\| uses = <vote slug="adhd-atomoxetine-use">Attention-deficit/hyperactivity disorder (FDA, ages 6+ and adult; the first non-controlled FDA-approved ADHD medicine)</vote>
	\| uses =		\| starting_dose = Children ≤70 kg: 0.5 mg/kg/day, titrate to 1.2 mg/kg/day after 3 days. Adults and children >70 kg: 40 mg PO once daily for 3 days, then 80 mg/day, then if needed 100 mg/day after 2-4 weeks
	\| starting_dose =		\| preparations = Capsules 10, 18, 25, 40, 60, 80, 100 mg
	\| preparations =		\| fda_max = 100 mg/day (adult); 1.4 mg/kg/day or 100 mg total (pediatric, whichever lower)
	\| fda_max =		\| pill_id =
	\| routes =		\| routes = Oral
	\| onset =		\| onset = ADHD effect emerges over 1-2 weeks (slower than psychostimulants); full effect 4-6 weeks
	\| duration =		\| duration = 24 hours (once-daily or split BID dosing)
	\| halflife =		\| halflife = ~5 hours in extensive CYP2D6 metabolizers; ~21 hours in CYP2D6 poor metabolizers<ref name="strattera-label">FDA Prescribing Information, Strattera (atomoxetine hydrochloride), Eli Lilly, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021411s044lbl.pdf</ref>
	~~\| bioavailability =~~		\| bioavailability = ~63% (oral; extensive first-pass)<ref name="strattera-label" />
	~~\| pregnancy~~ =		\| pregnancy = Limited human data.{{citation needed}}
	~~\| legal~~ =		\| legal = [[USLegal:Prescription only\|Rx-only]] in US. '''Not a controlled substance''', the principal clinical selling point versus psychostimulant ADHD options. Carries the antidepressant-class '''Boxed Warning''' for suicidal ideation in pediatric patients<ref name="strattera-label" />
	\| ~~intro =~~		\| mechanism = <vote slug="atomoxetine-mech-claim">Selective inhibition of the presynaptic norepinephrine transporter (NET). Increases extracellular norepinephrine and, in the prefrontal cortex, dopamine (since prefrontal dopamine reuptake is largely NET-mediated in that region, accounting for the ADHD efficacy despite no direct dopamine targeting).</vote> '''Not a psychostimulant''': no euphoric or rewarding effect, no abuse liability, no Schedule classification. CYP2D6 substrate with a strong pharmacogenomic signal: poor metabolizers have approximately 5-10-fold higher plasma exposure than extensive metabolizers, and CPIC provides CYP2D6 dosing guidance<ref name="cpic-atomoxetine">CPIC Guideline for Atomoxetine and CYP2D6 Genotype, 2019. https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/</ref>.
	~~\| pharmacokinetics~~ =
	~~\| pharmacodynamics~~ =
	\| ~~indications~~ =
	\| ~~dosing~~ =
	\| ~~effects~~ =
	~~\| interactions = <pharmaInteractions~~/>
	\| ~~pregnancy_details =~~
	~~\| monitoring~~ =
	~~\| counseling~~ =
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references~~ =
	}}		}}

	[[Category:~~Antidepressants~~]]		== References ==
	[[Category:~~Norepinephrine Reuptake Inhibitors (NRIs)~~]]		<references />

			[[Category:NRIs]]
			[[Category:ADHD medicines]]

MDElliottMD: Remove Category:Psychostimulants tag (not a psychostimulant — sedative/anxiolytic/anticonvulsant/non-stimulant carryover from Stimulants & Wake-Promoting Agents rename)

2026-05-18T00:48:03Z

Remove Category:Psychostimulants tag (not a psychostimulant — sedative/anxiolytic/anticonvulsant/non-stimulant carryover from Stimulants & Wake-Promoting Agents rename)

← Older revision		Revision as of 00:48, 18 May 2026
Line 33:		Line 33:
	[[Category:Antidepressants]]		[[Category:Antidepressants]]
	[[Category:Norepinephrine Reuptake Inhibitors (NRIs)]]		[[Category:Norepinephrine Reuptake Inhibitors (NRIs)]]
	~~[[Category:Psychostimulants]]~~

MDElliottMD: Recategorize: Stimulants -> Psychostimulants

2026-05-17T10:50:33Z

Recategorize: Stimulants -> Psychostimulants

← Older revision		Revision as of 10:50, 17 May 2026
Line 33:		Line 33:
	[[Category:Antidepressants]]		[[Category:Antidepressants]]
	[[Category:Norepinephrine Reuptake Inhibitors (NRIs)]]		[[Category:Norepinephrine Reuptake Inhibitors (NRIs)]]
	[[Category:~~Stimulants~~]]		[[Category:Psychostimulants]]

MDElliottMD: Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants

2026-05-17T10:44:46Z

Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants

← Older revision		Revision as of 10:44, 17 May 2026
Line 33:		Line 33:
	[[Category:Antidepressants]]		[[Category:Antidepressants]]
	[[Category:Norepinephrine Reuptake Inhibitors (NRIs)]]		[[Category:Norepinephrine Reuptake Inhibitors (NRIs)]]
	[[Category:Stimulants ~~& Wake-Promoting Agents~~]]		[[Category:Stimulants]]

MDElliottMD: Comprehensive categorization: +Norepinephrine Reuptake Inhibitors (NRIs), Stimulants & Wake-Promoting Agents

2026-05-15T18:42:06Z

Comprehensive categorization: +Norepinephrine Reuptake Inhibitors (NRIs), Stimulants & Wake-Promoting Agents

← Older revision		Revision as of 18:42, 15 May 2026
Line 32:		Line 32:

	[[Category:Antidepressants]]		[[Category:Antidepressants]]
			[[Category:Norepinephrine Reuptake Inhibitors (NRIs)]]
			[[Category:Stimulants & Wake-Promoting Agents]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:30:42Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:30, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:24Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =

MDElliottMD: Added empty fda_max parameter to MedTemplate call

2026-05-13T02:32:38Z

Added empty fda_max parameter to MedTemplate call

← Older revision		Revision as of 02:32, 13 May 2026
Line 8:		Line 8:
	\| starting_dose =		\| starting_dose =
	\| preparations =		\| preparations =
			\| fda_max =
	\| routes =		\| routes =
	\| onset =		\| onset =
Line 32:		Line 33:

	[[Category:Antidepressants]]		[[Category:Antidepressants]]

MDElliottMD: Expand stub to full MedTemplate parameter set

2026-05-13T01:00:00Z

Expand stub to full MedTemplate parameter set

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic           = Atomoxetine
+| generic            = Atomoxetine
-| brand             = Strattera
+| brand              = Strattera
-| classes           = NRI, ADHD medicine
+| structure          =
-| mechanism         = Selective norepinephrine reuptake inhibitor
+| classes            = NRI, ADHD medicine
 }}
 [[Category:Antidepressants]]

MDElliottMD: Auto-created stub

2026-05-13T00:00:00Z

Auto-created stub

New page

{{MedTemplate
| generic = Atomoxetine
| brand = Strattera
| classes = NRI, ADHD medicine
| mechanism = Selective norepinephrine reuptake inhibitor
}}
[[Category:Antidepressants]]